EMEA-001441-PIP03-17-M02
Key facts
| Invented name |
Ozempic
|
| Active substance |
semaglutide
|
| Therapeutic area |
Endocrinology, -gynacology-fertility-metabolism
|
| Decision number |
P/0461/2021
|
| PIP number |
EMEA-001441-PIP03-17-M02
|
| Pharmaceutical form(s) |
Solution for injection in pre-filled pen
|
| Condition(s) / indication(s) |
Treatment of obesity
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Novo Nordisk A/S
E-mail: paediatrics@novonordisk.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|